首页> 外文期刊>The New England journal of medicine >Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
【24h】

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.

机译:预防正在服用小剂量阿司匹林或萘普生的幽门螺杆菌感染患者的上消化道反复出血。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Many patients who have had upper gastrointestinal bleeding continue to take low-dose aspirin for cardiovascular prophylaxis or other non-steroidal antiinflammatory drugs (NSAIDs) for musculoskeletal pain. It is uncertain whether infection with Helicobacter pylori is a risk factor for bleeding in such patients. METHODS: We studied patients with a history of upper gastrointestinal bleeding who were infected with H. pylori and who were taking low-dose aspirin or other NSAIDs. We evaluated whether eradication of the infection or omeprazole treatment was more effective in preventing recurrent bleeding. We recruited patients who presented with upper gastrointestinal bleeding that was confirmed by endoscopy. Their ulcers were healed by daily treatment with 20 mg of omeprazole for eight weeks or longer. Then, those who had been taking aspirin were given 80 mg of aspirin daily, and those who had been taking other NSAIDs were given 500 mg of naproxen twice daily for six months. The patients in each group were then randomly assigned separately to receive 20 mg of omeprazole daily for six months or one week of eradication therapy, consisting of 120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, all given four times daily, followed by placebo for six months. RESULTS: We enrolled 400 patients (250 of whom were taking aspirin and 150 of whom were taking other NSAIDs). Among those taking aspirin, the probability of recurrent bleeding during the six-month period was 1.9 percent for patients who received eradication therapy and 0.9 percent for patients who received omeprazole (absolute difference, 1.0 percent; 95 percent confidence interval for the difference, -1.9 to 3.9 percent). Among users of other NSAIDs, the probability of recurrent bleeding was 18.8 percent for patients receiving eradication therapy and 4.4 percent for those treated with omeprazole (absolute difference, 14.4 percent; 95 percent confidence interval for the difference, 4.4 to 24.4 percent; P=0.005). CONCLUSIONS: Among patients with H. pylori infection and a history of upper gastrointestinal bleeding who are taking low-dose aspirin, the eradication of H. pylori is equivalent to treatment with omeprazole in preventing recurrent bleeding. Omeprazole is superior to the eradication of H. pylori in preventing recurrent bleeding in patients who are taking other NSAIDs.
机译:背景:许多上消化道出血的患者继续服用小剂量阿司匹林预防心血管疾病或其他非甾体抗炎药(NSAIDs)治疗肌肉骨骼疼痛。尚不确定幽门螺杆菌感染是否是此类患者出血的危险因素。方法:我们研究了有上消化道出血史的患者,这些患者感染了幽门螺杆菌并服用了小剂量阿司匹林或其他非甾体抗炎药。我们评估了根除感染或奥美拉唑治疗在预防复发性出血方面是否更有效。我们招募了经内窥镜检查证实患有上消化道出血的患者。每天用20毫克的奥美拉唑治疗8周或更长时间,即可治愈其溃疡。然后,每天服用阿司匹林的人每天服用80毫克阿司匹林,而服用其他非甾体抗炎药的人每天服用500毫克萘普生,持续六个月。然后将每组患者分别随机分配,分别接受奥美拉唑20毫克,持续六个月或一周的根除治疗,其中包括120毫克柠檬酸铋,500毫克四环素和400毫克甲硝唑,均给予四次每天一次,然后服用安慰剂六个月。结果:我们招募了400名患者(其中250例服用阿司匹林和150例服用其他非甾体抗炎药)。在服用阿司匹林的患者中,接受根除治疗的患者六个月内再次出血的可能性为1.9%,接受奥美拉唑的患者为0.9%(绝对差异为1.0%;差异的置信区间为-1.9,为95%)到3.9%)。在使用其他非甾体抗炎药的使用者中,接受根除治疗的患者再次出血的可能性为18.8%,使用奥美拉唑治疗的患者为4.4%(绝对差异为14.4%;差异的置信区间为95%,4.4%至24.4%; P = 0.005) )。结论:在服用小剂量阿司匹林的幽门螺杆菌感染和有上消化道出血史的患者中,根除幽门螺杆菌等同于用奥美拉唑治疗以防止复发性出血。奥美拉唑在预防服用其他非甾体抗炎药的患者复发性出血方面优于根除幽门螺杆菌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号